[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2003044166A3 - METHODS AND COMPOSITIONS FOR REGULATION OF GENE EXPRESSION THROUGH MODULATION OF mRNA TURNOVER - Google Patents

METHODS AND COMPOSITIONS FOR REGULATION OF GENE EXPRESSION THROUGH MODULATION OF mRNA TURNOVER Download PDF

Info

Publication number
WO2003044166A3
WO2003044166A3 PCT/US2002/036665 US0236665W WO03044166A3 WO 2003044166 A3 WO2003044166 A3 WO 2003044166A3 US 0236665 W US0236665 W US 0236665W WO 03044166 A3 WO03044166 A3 WO 03044166A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
mrna
gene expression
level
Prior art date
Application number
PCT/US2002/036665
Other languages
French (fr)
Other versions
WO2003044166A2 (en
Inventor
Ching-Yi Chen
Michael Karin
Original Assignee
Univ California
Ching-Yi Chen
Michael Karin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Ching-Yi Chen, Michael Karin filed Critical Univ California
Priority to AU2002359403A priority Critical patent/AU2002359403A1/en
Publication of WO2003044166A2 publication Critical patent/WO2003044166A2/en
Publication of WO2003044166A3 publication Critical patent/WO2003044166A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides means to modulate gene expression by destabilizing or stabilizing mRNA species. The invention provides compositions and methods for altering the level of RNA, and for screening test agents that alter RNA levels. The inventions's compositions and methods are useful in, for example, increasing the level of an mRNA and conversely in decreasing the level of mRNA by impacting the level of degradation of the mRNA.
PCT/US2002/036665 2001-11-15 2002-11-14 METHODS AND COMPOSITIONS FOR REGULATION OF GENE EXPRESSION THROUGH MODULATION OF mRNA TURNOVER WO2003044166A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002359403A AU2002359403A1 (en) 2001-11-15 2002-11-14 METHODS AND COMPOSITIONS FOR REGULATION OF GENE EXPRESSION THROUGH MODULATION OF mRNA TURNOVER

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33471201P 2001-11-15 2001-11-15
US60/334,712 2001-11-15

Publications (2)

Publication Number Publication Date
WO2003044166A2 WO2003044166A2 (en) 2003-05-30
WO2003044166A3 true WO2003044166A3 (en) 2003-12-31

Family

ID=23308474

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/036665 WO2003044166A2 (en) 2001-11-15 2002-11-14 METHODS AND COMPOSITIONS FOR REGULATION OF GENE EXPRESSION THROUGH MODULATION OF mRNA TURNOVER

Country Status (2)

Country Link
AU (1) AU2002359403A1 (en)
WO (1) WO2003044166A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227956B2 (en) 2013-04-17 2016-01-05 Pfizer Inc. Substituted amide compounds
CN108715830A (en) * 2018-05-04 2018-10-30 中南大学湘雅医院 Method for extracting exosome from urinary stem cell and application of exosome

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9085778B2 (en) 2006-05-03 2015-07-21 VL27, Inc. Exosome transfer of nucleic acids to cells
AU2011223789A1 (en) 2010-03-01 2012-09-20 Caris Life Sciences Switzerland Holdings Gmbh Biomarkers for theranostics
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
WO2015048844A1 (en) * 2013-10-02 2015-04-09 Xosoma Pty Ltd A method of producing exosomes
MA45481A (en) 2015-06-10 2018-04-18 Univ Texas USE OF EXOSOMES FOR THE TREATMENT OF DISEASES

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ALLMANG ET AL.: "The yeast exosome and human PM-Scl are related complexes of 3'->5' exonucleases", GENES DEV., vol. 13, 1999, pages 2148 - 2158, XP002187891 *
GELPI ET AL.: "Identification of protein components reactive with anti-PM/Scl autoantibodies", CLIN. EXP. IMMUNOL., vol. 81, 1990, pages 59 - 64, XP002970556 *
LAROIA ET AL.: "Control of mRNA decay by heat shock-ubiquitin-proteasome pathway", SCIENCE, vol. 284, 16 April 1999 (1999-04-16), pages 499 - 502, XP002970559 *
PORT ET AL.: "beta Adrenergic agonists that down-regulate receptor mRNA up-regulate a Mr 35,000 protein(s) that selectively binds to beta-adrenergic receptor mRNAs", J. BIOL. CHEM., vol. 267, no. 33, 25 November 1992 (1992-11-25), pages 24103 - 24108, XP002970557 *
WANG ET AL.: "Characterization of the proteins binding to the 3' regulatory region of the IL-3 gene in IL-3-dependent and autocrine-transformed hematopoiesis cells", LEUKEMIA, vol. 12, 1998, pages 520 - 531, XP002970558 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227956B2 (en) 2013-04-17 2016-01-05 Pfizer Inc. Substituted amide compounds
CN108715830A (en) * 2018-05-04 2018-10-30 中南大学湘雅医院 Method for extracting exosome from urinary stem cell and application of exosome
CN108715830B (en) * 2018-05-04 2019-08-06 中南大学湘雅医院 Method for extracting exosome from urinary stem cell and application of exosome

Also Published As

Publication number Publication date
WO2003044166A2 (en) 2003-05-30
AU2002359403A1 (en) 2003-06-10
AU2002359403A8 (en) 2003-06-10

Similar Documents

Publication Publication Date Title
WO2005044976A3 (en) Oligomeric compounds for use in gene modulation
EP1263765A4 (en) ALTERATION OF CELLULAR BEHAVIOR BY ANTISENSE MODULATION OF mRNA PROCESSING
EP1918368A3 (en) Enzyme stabilization by cationic surfactants
IS6950A (en) Composition of epothilone analogues and chemotherapeutic agents for the treatment of cell proliferative disorders
WO2005117938A3 (en) Methods of treating ocular conditions
WO2003044166A3 (en) METHODS AND COMPOSITIONS FOR REGULATION OF GENE EXPRESSION THROUGH MODULATION OF mRNA TURNOVER
WO2001096604A3 (en) Assay for genetic polymorphisms using scattered light detectable labels
WO2004024940A3 (en) Rna-mediated gene modulation
ATE381623T1 (en) METHOD FOR EXPRESSING PROTEIN WITH UNNATURAL AMINO ACID INTEGRATED THEREIN
WO2003057843A3 (en) Methods and materials for modulating trpc4
AU762955C (en) Methods and compositions useful for modulation of angiogenesis using tyrosine kinase SRC
WO2003070169A3 (en) Aminodiphosphonate apolipoprotein e modulators
WO2003050244A3 (en) Antisense modulation of g protein-coupled receptor etbr-lp-2 expression
WO2003006497A3 (en) Mutated photoproteins and their uses
WO2003057847A3 (en) METHODS AND MATERIALS FOR MODULATING ENaC-BETA
EP1211313A3 (en) Modulation of PDE11A activity
ATE539758T1 (en) RNAI MODULATION OF THE BCR-ABL FUSION GENE AND USES THEREOF
AU2003211040A8 (en) The eaat2 promoter and uses thereof
WO2005089730A3 (en) Dna pkinase inhibitors for treating cancer and diabetes
AU2002232521A1 (en) Compositions and methods for identifying agents which regulate chromosomal stability, gene activation and aging
DE60210970D1 (en) MUTANT FORMS OF ETXB AND CTXB AND THEIR USE AS CARRIER
WO2004050834A3 (en) GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER
WO2001067855A3 (en) Transgenic mice containing targeted gene disruptions
EP1908835A3 (en) Regulation of gene expression using single-chain, monomeric, ligand dependent polypeptide switches
EP1173458A4 (en) Antisense modulation of sra expression

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP